P R D Clephas, V W Zwartkruis, J Malgie, M W F van Gent, H P Brunner-La Rocca, M K Szymanski, V P van Halm, M L Handoko, W Kok, F W Asselbergs, R van Kimmenade, O Manintveld, N M D A van Mieghem, S L M A Beeres, M C Post, C J W Borleffs, R Tukkie, A Mosterd, G C M Linssen, R F Spee, M E Emans, T D J Smilde, J van Ramshorst, C Kirchhof, F Feenema-Aardema, C A da Fonseca, M van den Heuve, R Hazeleger, M van Eck, L van Heerebeek, H Boersma, M Rienstra, R A de Boer, J J Brugts
BACKGROUND AND AIMS: In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups. METHODS: The effect of PA-guided HF therapy was evaluated in the MONITOR-HF trial among predefined subgroups based on age, sex, atrial fibrillation, diabetes mellitus, left ventricular ejection fraction, HF aetiology, cardiac resynchronisation therapy, and implantable cardioverter defibrillator...
May 11, 2024: European Heart Journal